ERBB2 and gastric cancer: Espelin et al. discovered that nanoparticles targeting HER2 in two ways, using trastuzumab and liposomal-encapsulated doxorubicin (called MM-302), showed strong combined targeting and antitumor effects in breast and gastric cancer.